Trials / Withdrawn
WithdrawnNCT04838847
A Study to Evaluate the Immunogenicity and Safety of the SARS-CoV-2 mRNA Vaccine CVnCoV in Elderly Adults Compared to Younger Adults for COVID-19
COVID-19 (CoviCompareCV): A Phase 3, Non-randomized, Open Label Clinical Trial to Evaluate the Immunogenicity and Safety of the Investigational SARS-CoV-2 mRNA Vaccine CVnCoV Administered Intramuscularly in Adults Aged 65 Years or Above Compared to Younger Adults Aged 18-45 Years
- Status
- Withdrawn
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- CureVac · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
The primary objective of this study is to evaluate the humoral immune response to CVnCoV in elderly adults aged ≥65 years and younger adults aged 18-45 years, 14 days after the second dose administration.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | CVnCoV Vaccine | Intramuscular (IM) injection |
Timeline
- Start date
- 2021-10-01
- Primary completion
- 2022-01-01
- Completion
- 2022-09-01
- First posted
- 2021-04-09
- Last updated
- 2021-08-20
Source: ClinicalTrials.gov record NCT04838847. Inclusion in this directory is not an endorsement.